Randomized double-blind study of ONTAK® in cutaneous T-cell lymphoma patients

Journal of Drugs in Dermatology, Jan-Feb, 2004

Sponsored by Ligand Pharmaceuticals

The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.

Condition                    Treatment or Intervention  Phase

Lymphoma, T-Cell, Cutaneous  Drug: ONTAK[R]             Phase IV
Mycosis Fungoides
Sezary Syndrome

Study ID Number 93-04-11

NLM Identifier NCT00050999

COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale